Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).

R. Saito,Yasuyuki Kawamoto,Satoshi Yuki,Susumu Sogabe,Masayoshi Dazai,Ayumu Hosokawa,Kentaro Sawada,Atsushi Sato,Michio Nakamura,Kazuteru Hatanaka,Atsushi Ishiguro,Osamu Muto,Yoshiaki Shindo,Yasushi Tsuji,Miki Tateyama,Akira Ueda,Takahide Sasaki,M Katagiri,Naoya Sakamoto,Yoshito Komatsu

Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).

2021

TPS4152Background: Paclitaxel and ramucirumab combination therapy had become a standard regimen in the second-line treatment of advanced gastric cancer, since RAINBOW trial showed paclitaxel and ra...

Keywords:

in patient
advanced gastric cancer
Docetaxel
Oncology
Internal medicine
Medicine
Ramucirumab
Paclitaxel
Combination therapy
second line treatment
Regimen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations